The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: Combined results of two Phase III, multicenter, randomized clinical trials

Journal of Neurology

Volumn 256, Issue 6, 2009, Pages 888-897

  Uchiyama, Shinichiro ^a   Fukuuchi, Yasuo ^b   Yamaguchi, Takenori ^c  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b ASHIKAGA RED CROSS HOSPITAL   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Antiplatelet agents; Cardiovascular event; Cerebrovascular accident; Clopidogrel; Ticlopidine

Indexed keywords

CLOPIDOGREL; TICLOPIDINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AORTA ANEURYSM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAINSTEM HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART INFARCTION; HUMAN; JAPANESE; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STROKE; TREATMENT OUTCOME; VASCULAR DISEASE;

AGED; BRAIN INFARCTION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; JAPAN; LIVER; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; STROKE; TICLOPIDINE; TREATMENT OUTCOME;

EID: 67650395569     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-009-5035-4     Document Type: Article

References (18)

1. Japanese Statistics and Information Department. Abridged life tables for Japan 2005. http://www.mhlw.go.jp 2005. Accessed 26 Feb 2007
2. M Kubo Y Kiyohara I Kato 2003 Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: The Hisayama study Stroke 34 2349 2354 (Pubitemid 37221940)
3. DB Hier MA Foulkes M Swiontoniowski 1991 Stroke recurrence within 2 years after ischemic infarction Stroke 22 155 161
4. Y Shinohara 2006 Regional differences in incidence and management of stroke-is there any difference between Western and Japanese guidelines on antiplatelet therapy? Cerebrovasc Dis 21 Suppl. 1 17 24 (Pubitemid 43254157)
5. Joint Committee on Guidelines for the Management of Stroke (2004) Japanese guidelines for the management of stroke (in Japanese). Kyowa Kikaku Ltd, Tokyo
6. T Yamazaki S Goto H Shigematsu 2007 Prevalence, awareness, and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Results from domestic baseline data of the Reduction of Atherothrombosis for Continued Health (REACH) registry Circ J 71 995 1003 (Pubitemid 46998011)
7. WK Hass JD Easton Adams HP Jr 1989 A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group N Engl J Med 321 501 507 (Pubitemid 19203874)
8. M Mizushima N Iwata TT Fujimoto K Ishikawa K Fujimura 2005 Patient characteristics in ticlopidine hydrochloride-induced liver injury: case-control study Hepatol Res 33 234 240 (Pubitemid 41794212)
9. CAPRIE Steering Committee 1996 A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1329 1339
10. LA Harker JP Boissel AJ Pilgrim M Gent 1999 Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering committee and investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events Drug Saf 21 325 335
11. Y Fukuuchi H Tohgi T Okudera 2008 A randomized, double-blind study comparing the safety and efficacy of clopidogrel versus ticlopidine in Japanese patients with noncardioembolic cerebral infarction Cerebrovasc Dis 25 40 49 (Pubitemid 351280374)
12. 2 synthesized enzyme inhibitor CV-4151 in TIA: a double-blind comparison with ticlopidine Igaku No Ayumi 175 441 460
13. S Maruyama S Uchiyama H Tohgi 1995 Efficacy of an antiplatelet agent, E5510, for recurrence of cerebrovascular events in transient ischemic patients: a double-blind comparison with ticlopidine hydrochloride Rinsho Hyoka (clinical evaluation) 23 595 628
14. GJ Hankey CLM Sudlow DW Dunbabin 2000 Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials Stroke 31 1779 1784 (Pubitemid 30437537)
15. Hirata K, Takagi H, Yamamoto M, et al (2008) Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 8:29-33
16. F Gotoh H Tohgi S Hirai 2000 Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction J Stroke Cerebrovasc Dis 9 147 157 (Pubitemid 30480490)
17. DC Bezerra J Bogousslavsky 2005 Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives Cerebrovasc Dis 20 Suppl 2 109 118 (Pubitemid 44689466)
18. PG Steg DL Bhatt PW Wilson 2007 One-year cardiovascular event rates in outpatients with atherothrombosis JAMA 297 1197 1206 (Pubitemid 46465728)